capital · May 16, 2026
Spectral Medical Announces Q1 2026 Results and Tigris Trial Progress
Share the canonical public link.
Spectral Medical reported first quarter 2026 financial results on May 8, 2026, including continued Tigris trial advancement. Vantive committed an additional US$1.0 million funding tranche on May 7, 2026. The Tigris manuscript appeared in The Lancet Respiratory Medicine on March 23, 2026. Spectral Medical focuses on PMX therapy regulatory approval.
Spend governor blocked model creation: provider_circuit_open (lane=dev, provider=together)